GlassScriptPhysician profile
Michael P Graham
NPI 1518935907
$5,283.54
in general payments reported to CMS, 2019-2025
16 companies · $566 in 2025
The $566 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $484 · 2020: $233 · 2021: $632 · 2022: $671 · 2023: $969 · 2024: $1,729 · 2025: $566.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,406 · Travel and Lodging: $857.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,406.10 |
| Travel and Lodging | $857.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,308.20 | 2019-2025 | Lensx, Rocklatan, Clareon |
| Johnson & Johnson Surgical Vision, INC. | $662.21 | 2019-2023 | Tecnis Iol |
| Abbvie INC. | $538.05 | 2022-2025 | |
| Rayner Intraocular Lenses Limited | $341.24 | 2023-2025 | Rayone Aspheric, Rayone Emv, Rayone Spheric |
| Rxsight INC | $309.99 | 2022-2024 | Rxsight Contact Lens, Rxsight Injector Handpiece, Rxsight Injector Cartridge |
| Sun Pharmaceutical Industries INC. | $233.29 | 2019-2024 | Cequa |
| Bausch & Lomb Americas INC. | $163.85 | 2023-2025 | Vyzulta, Miebo, Prolensa |
| Aerie Pharmaceuticals, INC. | $149.60 | 2021 | |
| Carl Zeiss Meditec USA, INC. | $143.71 | 2022-2023 | Callisto Eye |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $109.47 | 2021 | |
| Glaukos Corporation | $96.09 | 2024 | Idose |
| Allergan, INC. | $73.81 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $61.53 | 2019-2020 | |
| Oyster Point Pharma, INC. | $55.83 | 2023 | Tyrvaya |
| Ocular Therapeutix, INC. | $22.24 | 2025 | Dextenza |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $14.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Graham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.